Toggle navigation
CN
Home
About Us
R&D
Our Science & Technology
Our Pipeline
Recent News
Contact Us
Recent News
Corporate News
Overland ADCT BioPharma Enters into a Strategic Partnership with Orient EuroPharma to Address the Unmet Needs of Lymphoma Patients in Taiwan and Singapore
2022-07-12
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial
2022-07-11
Overland ADCT Appoints Shirley Xu as Chief Medical Officer
2021-10-21
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma
2021-10-21
Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer
2021-10-21
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore
2021-10-21